膜性肾病的治疗标准
本文综述膜性肾病(MN)的病理生理新进展,包括足细胞靶抗原的鉴定与致病通路,并总结当前治疗标准与新兴疗法。利妥昔单抗是初治常用方案,但部分患者耐药,需细胞毒治疗;新型抗CD20抗体、靶向CD38阳性浆细胞及抗补体治疗正在耐药患者中研究。
要点
- 利妥昔单抗是膜性肾病初始治疗的常用组成部分,部分患者可能耐药而需细胞毒治疗。
- MN的病理认识已进展至特定足细胞抗原自身抗体及致病通路的层面。
- 新型抗CD20抗体、靶向CD38阳性浆细胞和抗补体治疗正在传统治疗耐药患者中研究。
核心结论
- 利妥昔单抗是MN初始治疗的常用方案,但部分患者耐药需替代药物;多种新兴疗法正在耐药患者中研究。
研究设计与样本
- 本文为综述,聚焦MN病理生理新进展(含靶抗原鉴定)与当前治疗标准,侧重达成缓解和预防疾病进展的循证干预。
主要发现
- 已鉴定针对新型足细胞抗原的特定自身抗体并阐明复杂致病通路。
- 部分MN患者可能对利妥昔单抗耐药,需使用细胞毒治疗等替代药物。
- 新型抗CD20抗体、靶向CD38阳性浆细胞治疗及抗补体治疗正在传统治疗耐药患者中研究。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Membranous nephropathy (MN) is characterized by deposition of immune complexes leading to thickening of glomerular basement membranes. Over time, the understanding of MN has evolved, with the identification of specific autoantibodies against novel podocyte antigens and the unraveling of intricate pathogenic pathways. Although the anti-CD20 monoclonal antibody rituximab is favored as part of the initial therapy in MN, a subgroup of MN patients may be resistant to rituximab necessitating the use of alternative agents such as cytotoxic therapies. In addition, newer agents such as novel anti-CD20 monoclonal antibodies, therapies targeting the CD38-positive plasma cells and anti-complement therapy are being studied in patients who are resistant to traditional treatment strategies. This manuscript furnishes a review of the novel developments in the pathophysiology of MN including the identification of target antigens and current treatment standards for MN, concentrating on evidenced-based interventions designed to attain remission and to prevent disease progression.
引用
- Radhakrishnan Y, Zand L, Sethi S, et al. Membranous nephropathy treatment standard. Nephrol Dial Transplant. 2024. PMID: 37934599. doi:10.1093/ndt/gfad225
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。